Sinopharm 's COVID-19 vaccine was less effective in offering protection against the disease among the elderly, according to the results of a Hungarian study. The study of 450 participants who had received two doses of the vaccine showed measurable antibody levels were present in about 90% of people under the age of 50, but the protection reduced as age increased. But the authors warned that the reliable estimation of a direct relationship between the risk of the COVID-19 disease, hospitalization, or death and the antibody levels after vaccination is extremely difficult. Sinopharm, formally known as China National Pharmaceutical Group, was not immediately available for comment. A recent study showed the vaccine elicited weaker antibody responses against the Delta variant, which was first found in India and is now the dominant variant worldwide.

Source: Mint July 23, 2021 11:37 UTC